


PHARMACEUTICAL 2022

LIFECORE BIOMEDICAL INC. \DE\ Rank 282 of 466





LANDEC



PHARMACEUTICAL 2022

LIFECORE BIOMEDICAL INC. \DE\ Rank 282 of 466

The relative strengths and weaknesses of LIFECORE BIOMEDICAL INC. \DE\ are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIFECORE BIOMEDICAL INC. \DE\ compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 106% points. The greatest weakness of LIFECORE BIOMEDICAL INC. \DE\ is the variable Assets, Current, reducing the Economic Capital Ratio by 113% points.

The company's Economic Capital Ratio, given in the ranking table, is 79%, being 0.97% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	148,321
Cost of Goods Sold	462,687
Intangible Assets	69,386
Liabilities, Current	101,888
Liabilities, Non-Current	168,501
Other Assets	105,658
Other Compr. Net Income	1,450
Other Expenses	26,927
Other Liabilities	29,751
Other Net Income	-11,626
Other Revenues	544,161
Property and Equipment	179,559
Research and Development	10,222
Selling, General and Administrative Expense	65,364

Output Variable	Value in 1000 USD
Assets	502,924
Liabilities	300,140
Expenses	565,200
Revenues	544,161
Stockholders Equity	202,784
Net Income	-32,665
Comprehensive Net Income	-31,940
Economic Capital Ratio	79%

LANDEC

